BioLineRx Signs Exclusive License Agreement With Yissum For Oral Phase II Ready Treatment BL-7040 For Inflammatory Bowel Disease
BioLineRx (TASE:BLRX), a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases. BL-7040 has dual activity on both the nervous and immune systems, rendering it highly suitable for treating both neurological diseases and immune system related conditions such as inflammatory or autoimmune diseases. It was invented by Professor Hermona Soreq, from the Alexander Silberman Institute of Life Sciences, Faculty of Science and the Edmond and Lily Safra Center of Brain Sciences at the Hebrew University of Jerusalem.
Revising MRE Protocol May Reduce Costs, Complexity While Maintaining Integrity Of Diagnosis For Crohn's Disease
A new study from Rhode Island Hospital has found that MR enterography (MRE) without the use of an anti-peristaltic agent were as reliable as CT enterography (CTE) in determining the presence of Crohn's disease. Additionally, MRE reduces the patient's exposure to ionizing radiation. The study is now published online in advance of print in the European Journal of Radiology. Lead author David J. Grand, M.D., director of the Body MRI program at Rhode Island Hospital, found that MR enterography without anti-peristaltic agents results in high diagnostic confidence for the presence or absence of Crohn's disease when compared to CT enterography. To limit exposure to ionizing radiation in young patients, MR enterography may be considered a first-line study for the evaluation of known or suspected Crohn's disease.
When a dog turns up in their consulting room with chronic diarrhoea, vomiting and weight loss, then it is quite likely that the vet will call it a case of inflammatory bowel disease. But that is probably the only thing that they can say with any confidence after identifying one of the most enigmatic and frustrating conditions seen in small animal practice. The cause of the disease is uncertain, the best treatment is still a mystery and even in those patients that do appear to be getting better, then the owner must appreciate that their pet's condition is only under temporary control, it is rarely ever cured. However, first opinion practitioners may have a better idea of the task awaiting them and improve the odds of a satisfactory response, after attending the session on the diagnosis and treatment of canine disease by Alex German at this year's BVA Congress.
At the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas, several studies of the effectiveness of non-X-ray techniques to evaluate Crohn's disease revealed that diagnostic strategies such as capsule endoscopy (CE) and magnetic resonance enteroscopy (MRE) are useful in managing patients with inflammatory bowel disease (IBD) and avoiding ionizing radiation. IBD Patients Exposed to Significant Ionizing Radiation Radiographic imaging is an important tool for diagnosis and management of IBD. In the study, "Effect of Age, Gender, and Ethnicity on Radiation Exposure among a Multi-Ethnic IBD Population of Low Socioeconomic Status, " researcher Jason Hou, M.D. and colleagues from Baylor College of Medicine, noted a lack of data quantifying radiation exposure in IBD patients.
Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists. More than half the people in the world are infected with H. pylori, although it is very unusual to find it in the United States. But this research shows there may be an inflammation control benefit to hosting the H. pylori infection, says Peter Higgins, M.D., Ph.D., M.Sc., lead author of the study published last week in the journal Inflammatory Bowel Diseases. "If we have evolved to live with certain bugs, maybe there is a reason, " said Higgins, assistant professor of gastroenterology in U-M's Department of Internal Medicine. "This research demonstrates that having H. pylori in your stomach could have beneficial immune effects in other parts of the body.